

UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS

IN RE: NEXIUM (ESOMEPRAZOLE)
ANTITRUST LITIGATION

)
)
)
)
)
)
)
MDL NO. 2409

CIVIL ACTION NO.
12-MD-02409-WGY

JURY VERDICT

1. Did AstraZeneca exercise market power within the relevant market?

_____ no ✓ yes
2. Did the settlement of the AstraZeneca-Ranbaxy patent litigation include a large and unjustified payment by AstraZeneca to Ranbaxy?

_____ no ✓ yes
3. Was AstraZeneca's Nexium settlement with Ranbaxy unreasonably anticompetitive, i.e. did the anticompetitive effects of that settlement outweigh any pro-competitive justifications?

_____ no ✓ yes
4. Had it not been for the unreasonably anticompetitive settlement, would AstraZeneca have agreed with Ranbaxy that Ranbaxy might launch a generic version of Nexium before May 27, 2014?

✓ no _____ yes
5. If so, what would be the effective date of such a license?

_____, 20_____
- 6.a. Had it not been for the unreasonably anticompetitive settlement, would Ranbaxy have agreed with Teva to launch a generic version of Nexium before May 27, 2014?

_____ no _____ yes

6.b. If so, when would Teva have launched?

_____, 20____

7. If a generic version of Nexium had come to market, would an authorized generic have entered at or about the same time?

_____ no _____ yes

Date: 12/5/14

M. Hamilton
Forelady